Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

This study has been completed.

Sponsor:

Information provided by:

Eli Lilly and Company

ClinicalTrials.gov Identifier:

NCT00415636

First received: December 21, 2006

Last updated: August 30, 2010

Last verified: August 2010

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	July 2010
Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)